CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,205,000)	$ (11,057,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	485,000	837,000
Depreciation and amortization	642,000	613,000
Changes in operating assets and liabilities:
Trade and other receivables	(142,000)	(4,678,000)
Inventories	8,864,000	(9,088,000)
Prepaid expenses	72,000	116,000
Other non-current assets	9,000	78,000
Accounts payable	(2,514,000)	222,000
Accrued clinical trial and related fees	254,000	(1,017,000)
Accrued payroll and related expenses	(1,240,000)	(2,168,000)
Deferred revenue	(15,067,000)	11,501,000
Customer deposits	(2,695,000)	(2,481,000)
Other accrued expenses and current liabilities	46,000	(819,000)
Deferred rent, less current portion	281,000	19,000
Net cash used in operating activities	(12,210,000)	(17,922,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment acquisitions	(1,338,000)	(275,000)
Decrease (increase) in other assets	935,000	(100,000)
Net cash used in investing activities	(403,000)	(375,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs of $111,000 and $55,000, respectively	4,193,000	2,115,000
Proceeds from exercise of stock options	34,000	0
Dividends paid on Series E preferred stock	(1,081,000)	(1,035,000)
Principal payments on capital lease	(76,000)	0
Net cash provided by financing activities	3,070,000	1,080,000
NET DECREASE IN CASH AND CASH EQUIVALENTS	(9,543,000)	(17,217,000)
CASH AND CASH EQUIVALENTS, beginning of period	46,799,000	61,412,000
CASH AND CASH EQUIVALENTS, end of period	37,256,000	44,195,000
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accounts payable and other liabilities for purchase of property and equipment and other assets	$ 748,000	$ 444,000